Collaborative Drug Therapy Management (CDTM)Collaborative Drug Therapy Management (CDTM) allows qualified pharmacists to engage in a formal collaborative practice arrangement with a physician, so long as the pharmacist is practicing in facilities regulated by article twenty-eight of the public health law, including any diagnostic center, treatment center, or hospital-based outpatient departments (including outpatient clinics). This protocol-based arrangement, after being given consent by the patient, allows the pharmacist to adjust or manage a drug regimen for a specific disease or disease state. CDTM has been successfully used throughout New York to improve patient care outcomes, improve medication adherence and decrease health care costs. The authority to engage in CDTM is set to sunset by July, 2022. Please inform your legislators of the importance of CDTM! Having to combat unnecessary sunset every two years is potentially stopping the robust development of these needed services. See fact sheet below. Collaborative Drug Therapy Management (CDTM) 2020 CDTM Fact Sheet
Development of a CDTM Practice Scope of Practice Advancement NYSCHP believes that pharmacists should be able to practice at the top of their license. Unfortunately, state and federal laws/regulations restrict the care pharmacists are able to provide. ASHP, in collaboration with other national pharmacy groups and state affiliates like NYSCHP, submitted extensive recommendations to CMS regarding the elimination of regulations that limit pharmacists from practicing at the top of their license. CMS requested additional input and recommendations under the Oct. 3, 2019, Executive Order “Protecting and Improving Medicare for Our Nation’s Seniors.” Comments to CMS regarding optimizing scope of practice for Pharmacists |